Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics

Stock Information for Dyadic International Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Dyadic International Inc.

Dyadic and BRIG BIO Sign Development & Commercialization Agreement to Bring Animal-Free Bovine Alpha-Lactalbumin to Global Nutrition Markets
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
Dyadic to Report Third Quarter 2025 Financial Results on Wednesday, November 12, 2025
Dyadic Applied BioSolutions Announces Milestone Achievements and Recent Company Developments
Dyadic to Present at Investor Conferences and BPI East
Dyadic Reports Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
Dyadic to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
UPDATE: Dyadic International, Inc. Announces Pricing of Public Offering of 6,052,000 Shares of Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.